



Date: January 24, 2025

To,  
**BSE Limited**  
Phiroze Jeejeebhoy Towers  
Dalal Street,  
Mumbai – 400 001  
**Scrip Code: 543434**

To,  
**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G  
Bandra Kurla Complex  
Bandra (E), Mumbai – 400 051  
**Scrip Symbol: SUPRIYA**

Dear Sir (s),

**Sub: Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024**

Pursuant to the Securities and Exchange Board of India circular no. SEBI/HO/CFD/CFD-PoD2/CIR/P/2024/185 dated December 31, 2024, please find attached the Integrated Filing (Financial) for the quarter and nine months ended December 31, 2024.

Kindly take the above said information on your records.

Thanking you,

Yours faithfully,

**For Supriya Lifescience Limited**

**Shweta Singh**  
**Company Secretary & Compliance Officer**  
**Membership No.: A44973**

---

**Corporate office** : 207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai – 400 063. Maharashtra, India.  
Tel: +91 22 40332727 / 66942507 Fax : +91 22 26860011 GSTIN: 27AALCS8686A1ZX  
CIN: L51900MH2008PLC180452 E-mail: [supriya@supriyalifescience.com](mailto:supriya@supriyalifescience.com) Website: [www.supriyalifescience.com](http://www.supriyalifescience.com)

**Factory** : A-5/2, Lote Parshuram Industrial Area, M.I.D.C. Tal.– Khed, Dist. – Ratnagiri, Pin :415 722, Maharashtra, India.  
Tel: +91 2356 272299 Fax: +91 2356 272178 E-mail: [factory@supriyalifescience.com](mailto:factory@supriyalifescience.com)

**SUPRIYA LIFESCIENCE LIMITED**  
CIN No: L51900MH2008PLC180452

207/208, Udyog Bhavan, Sonawala Road, Goregaon (East), Mumbai - 400063. CIN: L51900MH2008PLC180452  
Tel No.: +91 22 40332727; E-mail: cs@supriyalifescience.com; Website: www.supriyalifescience.com



(₹ In million)

**Part I -Statement of Standalone Unaudited Financial Results for the Quarter and Nine month ended December 31, 2024**

| Sr.No. | Particulars   | Quarter ended   | Quarter ended   | Quarter ended   | Nine month ended | Nine month ended | Year ended      |
|--------|---|-----------------|-----------------|-----------------|------------------|------------------|-----------------|
|        |   | 31-12-2024      | 30-09-2024      | 31-12-2023      | 31-12-2024       | 31-12-2023       | 31-03-2024      |
|        |   | Unaudited       | Unaudited       | Unaudited       | Unaudited        | Unaudited        | Audited         |
|        | <b>Income</b>   |                 |                 |                 |                  |                  |                 |
| I      | Revenue from Operations   | 1,856.48        | 1,661.02        | 1,400.74        | 5,123.76         | 4,121.89         | 5,703.70        |
| II     | Other Income  | 20.98           | 25.18           | 30.65           | 68.40            | 84.50            | 106.35          |
| III    | <b>Total Income</b>   | <b>1,877.45</b> | <b>1,686.20</b> | <b>1,431.39</b> | <b>5,192.16</b>  | <b>4,206.39</b>  | <b>5,810.05</b> |
| 2      | <b>Expenses</b>   |                 |                 |                 |                  |                  |                 |
|        | a) Cost of Materials Consumed   | 135.97          | 615.81          | 448.43          | 1,309.05         | 1,430.74         | 1,914.30        |
|        | b) Purchase of Stock in Trade   | -               | -               | -               | -                | -                | -               |
|        | c) Change in inventories of finished goods , work in progress & stock in trade.   | 481.82          | (156.06)        | 97.78           | 254.46           | 204.06           | 303.11          |
|        | d. Employee benefit expenses  | 197.72          | 196.85          | 175.64          | 595.42           | 504.94           | 676.38          |
|        | e. Finance Cost   | 5.07            | 4.27            | 4.94            | 12.68            | 15.09            | 21.10           |
|        | f. Depreciation & amortisation expense  | 49.64           | 47.44           | 39.60           | 143.63           | 118.97           | 158.11          |
|        | g. Other expenditure  | 381.44          | 357.25          | 264.00          | 1,032.72         | 807.44           | 1,080.15        |
| IV     | <b>Total Expenses</b>   | <b>1,251.65</b> | <b>1,065.56</b> | <b>1,030.39</b> | <b>3,347.96</b>  | <b>3,081.24</b>  | <b>4,153.15</b> |
| V      | Profit/(loss) before Exceptional Items & Tax (III -IV)                            | 625.80          | 620.64          | 400.99          | 1,844.20         | 1,125.15         | 1,656.90        |
| VI     | Exceptional Items   | -               | -               | -               | -                | -                | -               |
| VII    | <b>Profit/(loss) before Tax (V-VI)</b>  | <b>625.80</b>   | <b>620.64</b>   | <b>400.99</b>   | <b>1,844.20</b>  | <b>1,125.15</b>  | <b>1,656.90</b> |
| VIII   | <b>Tax Expense</b>  |                 |                 |                 |                  |                  |                 |
|        | a) Current Tax  | 137.72          | 154.46          | 96.55           | 438.85           | 281.56           | 371.00          |
|        | b) Deferred Tax   | 20.25           | 4.69            | 6.57            | 29.58            | 21.77            | 94.76           |
| IX     | <b>Profit/(Loss) for the period from Continuing Operations (VII-VII)</b>          | <b>467.83</b>   | <b>461.49</b>   | <b>297.87</b>   | <b>1,375.76</b>  | <b>821.82</b>    | <b>1,191.14</b> |
| X      | Profit/(Loss) from discontinued operations before tax                             | -               | -               | -               | -                | -                | -               |
| XI     | Tax Expense of discontinued operations  | -               | -               | -               | -                | -                | -               |
| XII    | Profit/(Loss) from discontinued operations after tax (X-XI)                       | -               | -               | -               | -                | -                | -               |
| XIII   | <b>Profit/(Loss) for the period (IX+XII)</b>                                      | <b>467.83</b>   | <b>461.49</b>   | <b>297.87</b>   | <b>1,375.76</b>  | <b>821.82</b>    | <b>1,191.14</b> |
| XIV    | <b>Other Comprehensive Income</b>   |                 |                 |                 |                  |                  |                 |
|        | A (i) Items that will not be reclassified to profit or loss                       | 0.81            | (2.90)          | 3.61            | (2.83)           | 21.23            | 21.69           |
|        | (ii) Income Tax relating to items that will not be reclassified to profit or loss | -0.20           | 0.73            | (0.91)          | 0.71             | (5.34)           | (5.46)          |
|        | B (i) Items that will be reclassified to profit or loss                           | -               | -               | -               | -                | -                | -               |
|        | (ii) Income Tax relating to items that will be reclassified to profit or loss     | -               | -               | -               | -                | -                | -               |
| XV     | <b>Total Comprehensive Income for the period (XIII+XIV)</b>                       | <b>468.43</b>   | <b>459.33</b>   | <b>300.57</b>   | <b>1,373.65</b>  | <b>837.71</b>    | <b>1,207.37</b> |
| XVI    | Earnings per equity Share (for continuing operation):                             |                 |                 |                 |                  |                  |                 |
|        | (1) Basic (In ₹)  | 5.82            | 5.71            | 3.70            | 17.07            | 10.21            | 14.80           |
|        | (2) Diluted (In ₹)  | 5.82            | 5.71            | 3.70            | 17.07            | 10.21            | 14.80           |
| XVII   | Earnings per equity Share (for discontinued operation):                           |                 |                 |                 |                  |                  |                 |
|        | (1) Basic (In ₹)  | -               | -               | -               | -                | -                | -               |
|        | (2) Diluted (In ₹)  | -               | -               | -               | -                | -                | -               |
| XVIII  | Earnings per equity Share (for discontinued & continuing operations):             |                 |                 |                 |                  |                  |                 |
|        | (1) Basic (In ₹)  | 5.82            | 5.71            | 3.70            | 17.07            | 10.21            | 14.80           |
|        | (2) Diluted (In ₹)  | 5.82            | 5.71            | 3.70            | 17.07            | 10.21            | 14.80           |



---

See accompanying notes to the financial statements:

**Notes:-**

1. The unaudited Standalone financial results of the Company for the quarter and nine month ended December 31, 2024 have been prepared in accordance with the Indian Accounting Standards ("Ind AS") as prescribed under section 133 of the Companies Act, 2013 read with the Companies (India Accounting Standards) Rules, 2015, as ammended.
2. The above unaudited standalone financial results of the Company for the quarter and nine month ended December 31, 2024 have been reviewed by the Audit Committee on January 24, 2025 and thereafter approved by the Board of Directors at their meeting held on January 24, 2025.
3. The company operates in one reportable business segment of Pharmaceutical product including ingredients and intermediaries.
4. The figures of the previous periods have been regrouped wherever necessary to conform to the current period presentation.
5. The company does not have any subsidiary/associate/joint venture company as on December 31, 2024.

Place :- Mumbai  
Date :- January 24, 2025



For and on behalf of the board of directors of  
For Supriya Lifescience Limited

A handwritten signature in black ink, appearing to read "Dr. Satish Waman Wagh".

Dr. Satish Waman Wagh  
Chairman and Whole time director  
DIN: 01456982

B. Statement On Deviation Or Variation For Proceeds Of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc.- **Not Applicable**

C. **Format For Disclosing Outstanding Default On Loans And Debt Securities**

| Sr no    | Particular   | INR in crore |
|----------|--|--------------|
| <b>1</b> | <b>Loans / revolving facilities like cash credit from banks / financial institutions</b>         |              |
| A        | Total amount outstanding as on date  | 0            |
| B        | Of the total amount outstanding, amount of default as on date                                    | 0            |
| <b>2</b> | <b>Unlisted debt securities i.e. NCDs and NCRPS</b>  |              |
| A        | Total amount outstanding as on date  | 0            |
| B        | Of the total amount outstanding, amount of default as on date                                    | 0            |
| <b>3</b> | <b>Total financial indebtedness of the listed entity including short-term and long-term debt</b> | <b>0</b>     |

D. Format for disclosure of related party transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter) – **Not Applicable**

E. Statement On Impact Of Audit Qualifications (For Audit Report With Modified Opinion) Submitted Along-With Annual Audited Financial Results (Standalone And Consolidated Separately) (Applicable Only For Annual Filing i.e., 4th Quarter)- **Not applicable**



**KAKARIA AND ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS  
UJWAL K. KAKARIA B.Com., B.L., F.C.A.  
SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.  
JAIPRAKASH H. SHETHIYA B.Com, F.C.A.  
AMAR J. BHANUSHALI B.Com, D.T.M., F.C.A.  
VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF.:  
OUR REF. :  
DATE : 24.01.2025


**Independent Auditor's Review Report on Quarterly Unaudited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.**

To,  
Board of Directors of Supriya Lifescience Limited,

1. We have reviewed the accompanying statement of unaudited financial results of **Supriya Lifescience Limited** ("the Company") for the quarter ended 31<sup>st</sup> December, 2024, ("the Statement"), being submitted by the company pursuant to the requirements of Regulation 33 and 52 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended (the "Listing regulations")
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries,

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,  
Mumbai - 400 053. Email: [mumbai.kakaria@gmail.com](mailto:mumbai.kakaria@gmail.com)  
Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)

*Cee*



**KAKARIA AND ASSOCIATES LLP**  
CHARTERED ACCOUNTANTS  
UJWAL K. KAKARIA B.Com., B.L., F.C.A.  
SUBHASH S. KOTADIA B.Com. (HONS.) F.C.A.  
JAIPRAKASH H. SHETHIYA B.Com, F.C.A.  
AMAR J. BHANUSHALI B.Com, D.T.M., F.C.A.  
VINAYAK P. BAFANA B.Com., F.C.A.

YOUR REF.:  
OUR REF. :  
DATE : 24.01.2025

primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under or by the Institute of Chartered Accountants

of India and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated 14<sup>th</sup> October, 2021 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR, KAKARIA AND ASSOCIATES LLP  
Chartered Accountants  
FRN. 104558W/W100601



**Ujwal K. Kakaria**  
(Partner)  
M.NO. 035416



Date:- 24<sup>th</sup> January, 2025

Place: - Mumbai

UDIN: 25035416BMKTON7250

802, Lotus Trade Centre, Near D.N. Nagar Metro Station, New Link Road, Andheri - West,  
Mumbai - 400 053. Email: [mumbai.kakaria@gmail.com](mailto:mumbai.kakaria@gmail.com)  
Website: [www.kakariaassociates.com](http://www.kakariaassociates.com)